RCKT Rocket Pharmaceuticals Inc.

22.36
+2.65  (+13%)
Previous Close 19.71
Open 20.15
Price To Book 4.86
Market Cap 1,126,659,911
Shares 50,376,030
Volume 1,002,027
Short Ratio
Av. Daily Volume 223,625
Stock charts supplied by TradingView

NewsSee all news

  1. Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 "Process B" for Fanconi Anemia

    —Preliminary Phase 2 Data Anticipated in 2020— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood

  2. Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting

    —Event to Highlight Preliminary Data from the Phase 1 Trial of RP-L102 "Process B" for Fanconi Anemia and from the Phase 1 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I— Rocket Pharmaceuticals, Inc.

  3. Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the

  4. Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

    –First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 "Process A" for Fanconi Anemia– –Four Gene Therapies Now in the Clinic– –Initial Data from FA "Process B"

  5. Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 "Process B" for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting

    —Rocket Management to Hold a Breakout Session with KOLs to Discuss Data Following Presentation at 8:30 p.m. EST on December 8th— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 trial failed - noted July 7, 2017.
Trabodenoson and latanoprost
Glaucoma
Phase 1 data due 4Q 2019.
RP-L201
Leukocyte Adhesion Deficiency-I (LAD-I)
Phase 1 data to be presented at ASH December 8, 2019 at 6pm EST.
RP-L102
Fanconi Anemia (FA)
Phase 1 data due 2020.
RP-A501
Danon disease
Phase 1 trial has commenced with data due 2020.
RP-L301
Pyruvate Kinase Deficiency (PKD)
Phase 2 initiation of dosing announced December 6, 2019 with data due 2020.
RP-L102
Fanconi Anemia (FA)

Latest News

  1. Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 "Process B" for Fanconi Anemia

    —Preliminary Phase 2 Data Anticipated in 2020— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood

  2. Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting

    —Event to Highlight Preliminary Data from the Phase 1 Trial of RP-L102 "Process B" for Fanconi Anemia and from the Phase 1 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I— Rocket Pharmaceuticals, Inc.

  3. Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the

  4. Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

    –First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 "Process A" for Fanconi Anemia– –Four Gene Therapies Now in the Clinic– –Initial Data from FA "Process B"

  5. Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 "Process B" for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting

    —Rocket Management to Hold a Breakout Session with KOLs to Discuss Data Following Presentation at 8:30 p.m. EST on December 8th— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based

  6. Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is

  7. Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 "Process A" for Fanconi Anemia

    – Early Signs of Hematologic Correction in Initial Patients Who Received Adequate Drug Product– – First Four "Process A" Patients Demonstrate Long-Term Evidence of Increasing and Durable Engraftment Resembling FA

  8. Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress

    —New Long-Term "Process A" Data from the Phase 1/2 EUROFANCOLEN Trial of RP-L102 to be Featured in Oral Session— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy

  9. Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is

  10. Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

     –Rocket's Largest Lentiviral Pipeline Opportunity with an Estimated Prevalence of 3,000 to 8,000 Patients in the U.S. and EU– –Phase 1 Clinical Trial to Commence in the Fourth Quarter– Rocket Pharmaceuticals, Inc.

  11. Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine

    —First Demonstration of Successful Engraftment of Gene Corrected Hematopoietic Stem Cells Without the Use of Conditioning— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform

  12. Rocket Pharmaceuticals Announces First Patient Treated in Phase 1/2 Registrational Trial of RP-L201 for LAD-I

    - Preliminary Phase 1 Data Expected by the End of 2019 - Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that the first

  13. Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting

    — U.S. Phase 2 Trial to Use MMC-Resistance as Primary Endpoint, Supported by Additional Blood Count, Genetic and Phenotypic Assessments — — Global Product Licensure Strategy Aligned Across U.S. and E.U. — Rocket

  14. Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces participation at the following upcoming conferences: Citi's 14ᵗʰ Annual

  15. Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia

    —Phase 2 Trial to Commence Patient Enrollment in Europe— — Rocket-sponsored Registration-enabling Study Utilizing Optimized Process B— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based